Yvonne Greenstreet, Alnylam CEO (Photo courtesy Alnylam)
March 21, 2025 02:50 PM EDT
Pharma
FDA+

Al­ny­lam hopes its broad AT­TR-CM la­bel can give Amvut­tra an edge in heart dis­ease

Max Gelman

Senior Editor

Al­ny­lam will like­ly face chal­lenges in turn­ing a prof­it this year, de­spite ex­ec­u­tives promis­ing to do so. But the la­bel for its new­ly-ap­proved Amvut­tra in­di­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ahead of FDA de­ci­sion, Al­ny­lam faces the big ques­tion: Can it make mon­ey?

Six­teen-year-old dies af­ter re­ceiv­ing Sarep­ta’s Duchenne gene ther­a­py

Up­dat­ed: Im­muno­vant will not take rare dis­ease drug to reg­u­la­tors de­spite Phase 3 win

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

Trump think tank res­ur­rects in­ter­na­tion­al drug pric­ing mod­el to go af­ter 'glob­al free­load­ing'

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

A service from the Financial Times